Art Krieg

Art has worked in the oligonucleotide field since the 1980s. After discovering immune stimulatory CpG DNA in 1994, he co-founded Coley Pharmaceutical Group in 1997 to develop the technology, discovering and taking 4 novel CpG oligonucleotides into clinical development. In 2008, Pfizer acquired Coley and Art became Chief Scientific Officer of Pfizer’s Oligonucleotide Therapeutics Unit until they exited the field in 2011. Art subsequently co-founded RaNA Therapeutics, serving as its CEO through 2013, and served as CSO at Sarepta Therapeutics until July 2014. He co-founded the first antisense journal, Nucleic Acid Therapeutics, and the Oligonucleotide Therapeutic Society, for which he recently served as President. Art received an MD from Washington University and trained in internal medicine at the University of Minnesota and in rheumatology at the NIH before joining the faculty at the University of Iowa, becoming professor of internal medicine. He has published more than 250 scientific papers and is an inventor on >50 issued US patents covering oligonucleotide technologies.